Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
AlShehry NF, Shanker R, Zaidi SZA, AlGhmlas F, Motabi IH, Iqbal S, Butt AA, AlShehri H, Tailor IK, Altaf SY, AlGhamdi M, Marie M, AlFayez M, Al Zahrani K, Dwaimah M, Al-Halouli T, Al-Shakweer W, AlShehery MZ, Zaidi ARZ, Gill AM, Albtoosh BM, Ahmed M
Role of 18F-Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography Imaging in the Prediction of Prognosis in Patients With Indolent Lymphoma: Prospective Study
Role of 18F-FDG-PET/CT Imaging in the Prediction of Prognosis in Patients with Indolent Lymphoma: A Prospective Study
Nawal Faiez AlShehry;
Raja Shanker;
Syed Ziauddin Ahmed Zaidi;
Fahad AlGhmlas;
Ibraheem Hussein Motabi;
Shahid Iqbal;
Ahmad Ali Butt;
Hassan AlShehri;
Imran Khan Tailor;
Syed Yasir Altaf;
Mubarak AlGhamdi;
Mohammed Marie;
Mansour AlFayez;
Kamal Al Zahrani;
Mohammed Dwaimah;
Tahani Al-Halouli;
Wafaa Al-Shakweer;
Maied Zaher AlShehery;
Abdul Rehman Zia Zaidi;
Atta Munawar Gill;
Belal Mohammed Albtoosh;
Musab Ahmed
ABSTRACT
Background:
The role of FDG-PET in indolent lymphoma (INL) has been minimally studied.
Objective:
To assess the value of FDG-PET/CT in the prediction of prognosis in INL.
Methods:
We prospectively recruited 42 patients with indolent lymphomas. Two patients were excluded and 40 underwent a baseline PET/CT and follow up at various time points. Nine patients were observed, 7 received four doses of Rituximab alone, and 24 received chemoimmunotherapy. Metabolic response on follow-up PET/CT was assessed using SUVmax and Deauville criteria (DC). We aimed to obtain the best SUVmax/DC to predict optimal survival rates, risk stratification, and optimize therapeutic strategies. The mean follow-up from initial diagnosis was 33.83 months.
Results:
SUVmax <4.35 at interim PET/CT provided the best discriminator with progression-free survival (PFS) of 100% and median survival time of 106.67 months, as compared to 43.8% and 50.17 months respectively for SUVmax ≥4.35 (P=.041). This cut-off was also valuable in predicting overall survival (OS) at baseline, i.e. 100% OS with baseline SUVmax <4.35, versus 58.4% for SUVmax ≥4.35 (P=.133). OS of patients with baseline DC score <3.0 was 100%, with median OS 106.67 months.
Conclusions:
We demonstrated the utility of PET/CT in indolent lymphomas. SUVmax (<4.35 vs ≥4.35) at interim PET/CT performed best in predicting PFS.
Citation
Please cite as:
AlShehry NF, Shanker R, Zaidi SZA, AlGhmlas F, Motabi IH, Iqbal S, Butt AA, AlShehri H, Tailor IK, Altaf SY, AlGhamdi M, Marie M, AlFayez M, Al Zahrani K, Dwaimah M, Al-Halouli T, Al-Shakweer W, AlShehery MZ, Zaidi ARZ, Gill AM, Albtoosh BM, Ahmed M
Role of 18F-Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography Imaging in the Prediction of Prognosis in Patients With Indolent Lymphoma: Prospective Study